Funding received for EU project

LCGC Europe eNews

LCGC Europe eNews-12-12-2008, Volume 0, Issue 0

MIP Technologies AB is to receive funding for a four-year project that also includes funding for a three year PhD position...

MIP Technologies AB is to receive funding for a four-year project that also includes funding for a three year PhD position. The EU funded project, "New Molecular Purification Techniques for API Production" (Nemopur), under the European Commission's Marie Curie Initial Training network within the 7th Framework Programme, aims to offer a powerful and unique solution to the purification of active pharmaceutical ingredients (APIs) by combining organic solvent nanofiltration (OSN) with molecular imprinted polymers (MIPs). The project focus will be on the removal of contaminant organic compounds from APIs.

The network consists of three universities, two small- and medium-sized companies, including MIP Technologies and the four end-users; Hovione SA, UCB Pharma SA, GlaxoSmithKline Ltd and Lonza Ltd, who will provide input on the choice of purification systems and validation of the purification methods developed.

There is a growing expectation among patients regarding the efficacy, safety and purity of medicines, which has led an urgent need for new molecular purification technologies in pharmaceutical production. Nemopur aims to alter its approach to purifying API intermediates. An essential feature of this project will be the interdisciplinary nature of the partners and the fact that they bring inter-sectorial competence to the network, spanning academic, technology SME, and end-user sectors.

"We are very excited to be part of this EU-network. It is our belief that MIPs constitute a powerful technique for highly selective removal of impurities from API solutions," said Dr Ecevit Yilmaz, chief technology officer at MIP Technologies.

"Participating in this research programme will further strengthen MIP Technologies by facilitating the creation of novel MIP materials for large-scale processes, particularly important in the pharma and biopharma industries" said Anthony Rees, CEO at MIP Technologies.

For more information please visit the company's website at www.miptechnologies.com